Abstract: Objective: To investigate the efficacy of flupentixol melitracen on different stages of sudden deafness patients with anxiety and depression.Method: Totally one hundred and sixty-three sudden deafness patients with anxiety and depression were randomly divided into two groups:experimental group(81 cases) and control group (82 cases). All patients were given routine treatment for 2 weeks. The experimental group was given oral flupentixol melitracen (1 tablet/day)for a period of 3 months. The hearing, tinnitus effect and vertigo treatment course were observed and compared. Curing rate of tinnitus at 2 weeks, 3 months and 6 months after treatment, self-rating anxiety scale (SAS) and depressive state scale (self-rating depression scale, SDS) score were collected and compared.Result: Total efficiency of hearing and tinnitus of experimental group(86.42%,84.21%)were higher than those of the control group (67.07%, 61.29%); the vertigo cured the average treatment time of experimental group(5.79±2.22) days was less than that of the control group (10.21±3.42) days, all the differences were statistically significant (P<0.05). After the treatment, the average hearing thresholds of the two groups were lower than those before the treatment, and the hearing thresholds of the low frequency descent type, high-frequency descent type, flat down type and total deafness type in the experimental group were lower than those in the control group, all the differences were statistically significant (P<0.05). The tinnitus cure rate of the experiment group were higher than that of the control group at 3 months and 6 months after treatment, the differences were statistically significant (P<0.05); and after 3 months and 6 months treatment tinnitus cure rate of the experimental group was higher than that of after 2 weeks the treatment, the difference was statistically significant (P<0.05).The SAS and SDS scores of the two groups at 2 weeks, 3 months and 6 months were lower than those before treatment. The SAS and SDS scores decreased at 2 weeks, 3 months and 6 months after treatment in the experimental group. At the same time point after treatment, the SAS and SDS scores of the experimental group were lower thean those of the control group (P<0.05).Conclusion: For the sudden deafness patients with anxiety and depression, the combination of flupentixol melitracen on the basis of conventional therapy can improve the clinical efficacy, the patient's mental status and long-term therapeutic effect of tinnitus.